Nature's Sunshine Products, Inc
13.42-0.43 (-3.1%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · NATR · USD
Key Stats
Market Cap
236.67MP/E (TTM)
17.89Basic EPS (TTM)
0.75Dividend Yield
0%Recent Filings
8-K
Q2 Sales Beat Expectations
Nature's Sunshine reported Q2 2025 net sales up 4% to $114.8 million, driven by strength in Japan and Central Europe, while North America showed steady gains. GAAP net income surged to $5.3 million from $1.3 million last year, boosted by foreign exchange gains, though SG&A rose to 38.1% of sales from higher marketing spends. Adjusted EBITDA climbed 8% to $11.3 million. Full-year guidance lifted to $460-$475 million in sales.
10-Q
Q2 FY2025 results
Nature's Sunshine Products posted solid Q2 momentum, with net sales climbing 3.8% year-over-year to $114.8M, fueled by 5.4% growth in Asia and 4.2% in North America, while gross margin edged up to 71.7% from cost savings. Operating income dipped 24.2% to $4.3M amid higher SG&A from digital marketing pushes, yet net income surged 270.9% to $5.5M, boosted by $3.0M in foreign exchange gains. Diluted EPS rose to $0.28 from $0.07, aligning with 18,966,000 weighted shares. Cash stood at $81.3M with no revolver debt drawn, and free cash flow hit $4.5M (derived) after $2.5M capex; the firm agreed to buy out China joint ventures for $7.0M cash, securing full ownership pending approvals. Share repurchases totaled $12.4M. Ongoing U.S. trade control probes pose regulatory risks.
8-K
Joint venture buyback
Nature's Sunshine Products triggered a buyback of its China joint ventures after Fosun Pharma sold shares on June 27, 2025, dropping below the 5% threshold. On June 30, the company inked deals to acquire Fosun Industrial's 20% stakes in the Hong Kong and Shanghai ventures for $3.9 million and $3.1 million in cash, respectively, gaining full control of these key distribution channels. Closings hinge on Chinese regulatory nods. Full ownership sharpens focus on China operations.
8-K
Secondary offering and repurchase
Nature's Sunshine Products announced an underwritten secondary offering of 2,854,607 shares by Fosun Pharma USA at $12.00 per share, with the deal set to close around June 27, 2025. The company won't pocket any proceeds but plans a concurrent repurchase of up to $15.0 million in shares from underwriters, funded by cash and credit, to cancel them and trim outstanding stock. This offsets dilution while locking in a 90-day trading blackout for insiders. Repurchase hinges on offering success.
8-K
CEO steps down soon
Nature's Sunshine Products announced on June 2, 2025, that CEO Terrence Moorehead will step down effective upon successor appointment, after nearly seven years leading brand revitalization and digital growth. The board launched a search with a top firm, praising his foundation for future expansion. It reaffirmed full-year 2025 net sales and adjusted EBITDA outlook. Leadership transitions risk disrupting operations.
IPO
Employees
Sector
Industry
BFNH
BioForce Nanosciences Holdings,
0.80+0.00
HAIN
The Hain Celestial Group, Inc.
1.31-0.04
HCWC
Healthy Choice Wellness Corp.
0.64-0.01
HLF
Herbalife Ltd.
8.02-0.09
LFVN
Lifevantage Corporation
8.15-0.36
LIMX
Limitless X Holdings Inc.
2.20+0.03
NAII
Natural Alternatives Internatio
2.81-0.05
NPRFF
NEPRA FOODS INC.
0.09+0.01
NUS
Nu Skin Enterprises, Inc.
10.65-0.09
USNA
USANA Health Sciences, Inc.
19.61-0.72